Researchers at Scripps Research have pinpointed a molecular switch that appears to keep the brain's immune system stuck in the "on" position in Alzheimer's disease. Writing in Cell Chemical Biology on April 23, 2026, the team focused on STING, a protein that normally acts as part of the immune system's early-warning apparatus. In brain tissue from people with Alzheimer's, they found STING carrying a chemical modification called S-nitrosylation - a reaction involving sulfur, oxygen and nitrogen - that pushes the protein into overactivation.
That matters because the brain's resident immune cells, when chronically overactivated, produce inflammation that erodes the connections between neurons. Those connections, the synapses, are among the earliest casualties in Alzheimer's and correlate closely with cognitive decline. Identifying a specific chemical event that flips the inflammatory switch gives drug developers something concrete to aim at, rather than trying to dampen brain inflammation wholesale.
When the researchers blocked the modification of STING in a mouse model of the disease, neuroinflammation went down. The team also reported protection of the brain cell connections that are lost in Alzheimer's. Strengthening the case, they detected the same pathway activated in human Alzheimer's brain samples and in models built from human stem cells, not only in mice - a point the researchers themselves emphasized as the reason for their optimism.
This is preclinical work, and the distance between a validated target in mice and human brain cells and a drug that helps patients is considerable. What it offers for now is a specific, chemically defined handle on the inflammation side of Alzheimer's, a line of attack that runs alongside the amyloid- and tau-focused approaches that have dominated the field.